<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077128</url>
  </required_header>
  <id_info>
    <org_study_id>P11-984</org_study_id>
    <nct_id>NCT01077128</nct_id>
  </id_info>
  <brief_title>Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab</brief_title>
  <official_title>[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective

        -  To evaluate the quality of life of Adalimumab treated patients over a period of 12
           months

      Secondary objectives

        -  To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe
           chronic plaque psoriasis as prescribed by the dermatologists in day-to-day clinical
           practice and in accordance with the terms of the European marketing authorization.

        -  To evaluate changes in patients quality of life according to treatment response over a
           12-month period

        -  To observe and assess the long term use and safety of Adalimumab as prescribed by the
           dermatologist in a normal clinical setting and in accordance with the terms of the
           European marketing authorization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this post-marketing observational study in adult patients with moderate to severe
      chronic plaque psoriasis is to obtain further data on patient's Quality of Life and assess
      the impact of Adalimumab treatment on patient's quality of life in conditions of day-to-day
      clinical practice in Greece. This study will further assess the relationship between clinical
      outcomes and patient-reported outcomes. As this is an observational study, Abbott will not
      provide the study drug. Humira will be prescribed according to the routine medical practice.
      The participating physicians are free to determine the appropriate therapy for each patient
      and make treatment choices as deemed clinically necessary.

      The Dermatology Life Quality Index (DLQI) will be used to assess patient quality of life. The
      Dermatology Life Quality Index (DLQI) total scores range from 0 to 30, with 0 corresponding
      to the best quality of life and 30 to the worst. The Dermatology Life Quality Index (DLQI)
      has well-established reliability and validity as determined in several studies. Moreover, it
      is frequently used in clinical trials of psoriasis.

      The physician's global assessment of disease severity (PGA) will be used to measure patients'
      disease status at the time of assessment. It is a 6-point scale measuring the degree of
      overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe).

      Complementary, European Quality of Life-5 Dimensions health questionnaire (EQ5D) will be used
      as a measure of health outcome. This is applicable to a wide range of health conditions and
      treatments and it provides a simple descriptive profile and a single index value for health
      status. Health economic data will be collected by using European Quality of Life-5 Dimensions
      health questionnaire (EQ5D) questionnaire and data regarding patients hospitalisation due to
      psoriasis. Hospitalisation data will be collected 6 months before the period and throughout
      the observation period.

      Moreover, this study will observe the current medical practice in prescribing Adalimumab in
      Greece and more detailed data on prescription behavior will be collected. Guidelines have
      been developed in order to ensure that the new class of therapy (biologic agents) is
      introduced in a systematic and planned way to achieve the greatest possible benefit to people
      with psoriasis and to facilitate safe and effective prescribing. However, many issues are not
      fully addressed, such as recommendation regarding the amount of time for wash out of previous
      antipsoriatic drugs and combination therapies. Such issues remain at the discretion of the
      healthcare professional. Since this is an observational study the patient will be treated in
      accordance with the physician's usual and customary medical practice. Thus, the following
      information regarding the use of Adalimumab will be collected

        -  the previous systemic treatment history will be recorded including previous biological
           therapies that patient received, if any,

        -  wash out periods prior to initiating Adalimumab therapy, if any

        -  reasons for stopping previous treatment,

        -  combination of Adalimumab with other topical or systemic antipsoriatic agents, if
           applicable

      Furthermore, demographic data of patients suffering from psoriasis in Greece will be
      collected (age, gender, ethnicity) and disease data such as duration of the disease,
      involvement of nails or joints, geographic distribution of the disease in Greece will be
      collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of Dermatology Life Quality Index (DLQI) Scores</measure>
    <time_frame>12-month period, (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Experienced an Improvement in Disease Severity as Determined by the Physician's Global Assessment of Disease Severity (PGA) Scores</measure>
    <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>The Physician's Global Assessment of disease severity (PGA) was used to measure participants' disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Dermatology Life Quality Index (DLQI) Score by Physician's Global Assessment of Disease Severity (PGA) Response Groups and by Geographical Region</measure>
    <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>The average change in the Dermatology Life Quality Index (DLQI) score during the 12-month study was analyzed by the Physician's Global Assessment of disease severity (PGA) response and also by geographical location of study participants. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life. . In this table, a higher number means a greater improvement in the participants' quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting &quot;No Problem&quot; on the European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D)</measure>
    <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either &quot;problem&quot; or &quot;no problem&quot; with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline of European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Visual Analogue Scale (VAS) Scores</measure>
    <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either &quot;problem&quot; or &quot;no problem&quot; with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Long Term Use and Safety of Adalimumab as Prescribed by the Dermatologist in a Normal Clinical Setting and in Accordance With the Terms of the European Marketing Authorization</measure>
    <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant, which did not necessarily have a causal relationship with their treatment. Any worsening of a pre-existing condition or illness was considered an adverse event.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patients with psoriasis</arm_group_label>
    <description>All eligible patients with psoriasis treated with Adalimumab</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Adalimumab according to routine medical practice from hospital and
        private physicians.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate to severe chronic plaque psoriasis who are newly prescribed
             Humira (adalimumab) therapy (have never been treated with adalimumab before) and for
             whom the treating physician has made the decision that they are eligible for treatment
             with adalimumab in accordance with the terms of the local marketing authorization

          -  Patients with moderate to severe chronic plaque psoriasis for whom Adalimumab is
             indicated and has been prescribed according to the current approved local SPC as long
             as the first administration of adalimumab is not older than two months and they have
             not had dose interruptions since the initiation of adalimumab, and the Investigator
             can provide all the needed source documentation including a completed DLQI
             questionnaire at the start of Adalimumab treatment.

          -  Patient age ≥ 18

          -  Patient is willing to consent to data being collected and provided to Abbott

        Exclusion Criteria:

          -  Patients who meet contraindications as outlined in the latest version of the local
             approved SPC

          -  Patients who participate in another clinical/observational study

          -  Patients who are not willing to sign an Informed Consent Form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athina Katsavou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AbbVie Pharmaceuticals S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43746</name>
      <address>
        <city>Agrinio</city>
        <zip>301 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30197</name>
      <address>
        <city>Amaliada</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30039</name>
      <address>
        <city>Argos</city>
        <zip>21200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29903</name>
      <address>
        <city>Argyroupoli</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29819</name>
      <address>
        <city>Athens</city>
        <zip>10673</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29949</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30804</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30806</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38324</name>
      <address>
        <city>Athens</city>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22385</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29826</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29966</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29991</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30106</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30107</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30181</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30470</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30086</name>
      <address>
        <city>Chania, Crete</city>
        <zip>73136</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43744</name>
      <address>
        <city>Chania, Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30794</name>
      <address>
        <city>Crete</city>
        <zip>71409</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29937</name>
      <address>
        <city>Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29959</name>
      <address>
        <city>Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29969</name>
      <address>
        <city>Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38334</name>
      <address>
        <city>Drama</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30801</name>
      <address>
        <city>Florina</city>
        <zip>53100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29919</name>
      <address>
        <city>Giannitsa</city>
        <zip>58100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30202</name>
      <address>
        <city>Giannitsa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29970</name>
      <address>
        <city>Glyfada</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30013</name>
      <address>
        <city>Glyfada</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29823</name>
      <address>
        <city>Glyfada</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30193</name>
      <address>
        <city>Halandri</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30083</name>
      <address>
        <city>Kalamaria</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30143</name>
      <address>
        <city>Kallithea</city>
        <zip>17672</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47262</name>
      <address>
        <city>Katerini</city>
        <zip>60100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38329</name>
      <address>
        <city>Keratsini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30108</name>
      <address>
        <city>Kolonaki</city>
        <zip>10675</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30009</name>
      <address>
        <city>Kosmos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38323</name>
      <address>
        <city>Larissa</city>
        <zip>41100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38340</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29822</name>
      <address>
        <city>Livadeia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30180</name>
      <address>
        <city>Makri</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29834</name>
      <address>
        <city>Mitilini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30469</name>
      <address>
        <city>Mitilini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38326</name>
      <address>
        <city>N.Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30032</name>
      <address>
        <city>Neapoli</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30104</name>
      <address>
        <city>Pagkrati</city>
        <zip>11634</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29817</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29967</name>
      <address>
        <city>Peiraius</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38327</name>
      <address>
        <city>Peristeri</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30109</name>
      <address>
        <city>Petralona</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29824</name>
      <address>
        <city>Smyrni</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38325</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54643</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30769</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30170</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38331</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38332</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38333</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38335</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38337</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30203</name>
      <address>
        <city>Vari</city>
        <zip>16672</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29921</name>
      <address>
        <city>Volos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>September 13, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2014</results_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With Psoriasis</title>
          <description>All eligible patients with psoriasis treated with Adalimumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event and consent withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event and disease exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy/disease exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not available</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Psoriasis</title>
          <description>All eligible patients with psoriasis treated with Adalimumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Regions of Greece</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Attica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Macedonia and Thrace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thessaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peloponnese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North Aegean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ionian Islands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Aegean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epirus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of Dermatology Life Quality Index (DLQI) Scores</title>
        <description>DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.</description>
        <time_frame>12-month period, (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <population>Participants with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Psoriasis- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>Patients With Psoriasis- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O3">
            <title>Patients With Psoriasis- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O4">
            <title>Patients With Psoriasis- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Dermatology Life Quality Index (DLQI) Scores</title>
          <description>DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life.</description>
          <population>Participants with available data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="443"/>
                <count group_id="O4" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="6.3"/>
                    <measurement group_id="O2" value="9.3" spread="7.3"/>
                    <measurement group_id="O3" value="11.3" spread="7.8"/>
                    <measurement group_id="O4" value="12.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Experienced an Improvement in Disease Severity as Determined by the Physician’s Global Assessment of Disease Severity (PGA) Scores</title>
        <description>The Physician's Global Assessment of disease severity (PGA) was used to measure participants’ disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores was recorded.</description>
        <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <population>Participants with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Psoriasis- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>Patients With Psoriasis- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O3">
            <title>Patients With Psoriasis- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O4">
            <title>Patients With Psoriasis- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experienced an Improvement in Disease Severity as Determined by the Physician’s Global Assessment of Disease Severity (PGA) Scores</title>
          <description>The Physician's Global Assessment of disease severity (PGA) was used to measure participants’ disease status at the time of assessment. This tool is a horizontal visual analogue 6-point scale measuring the degree of overall psoriatic lesion severity, and scores range from 0 (clear) to 5 (very severe). The percentage of patients who showed an improvement from baseline in their PGA scores was recorded.</description>
          <population>Participants with available data at each time point</population>
          <units>Percentage of patients improving</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="470"/>
                <count group_id="O3" value="445"/>
                <count group_id="O4" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2"/>
                    <measurement group_id="O2" value="95.1"/>
                    <measurement group_id="O3" value="97.5"/>
                    <measurement group_id="O4" value="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Dermatology Life Quality Index (DLQI) Score by Physician’s Global Assessment of Disease Severity (PGA) Response Groups and by Geographical Region</title>
        <description>The average change in the Dermatology Life Quality Index (DLQI) score during the 12-month study was analyzed by the Physician’s Global Assessment of disease severity (PGA) response and also by geographical location of study participants. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life. . In this table, a higher number means a greater improvement in the participants’ quality of life.</description>
        <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <population>Participants with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>DLQI Score Change by PGA Response Group- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>DLQI Score Change by PGA Response Group- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O3">
            <title>DLQI Score Change by PGA Response Group- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O4">
            <title>DLQI Score Change by PGA Response Group- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O5">
            <title>DLQI Score Change Baseline to Month 12- Attica</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O6">
            <title>DLQI Score Change Baseline to Month 12- Central Greece</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O7">
            <title>DLQI Score Change Baseline to Month 12- Central Macedonia</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O8">
            <title>DLQI Score Change Baseline to Month 12- Crete</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O9">
            <title>DLQI Score Change Baseline to Month 12- East Macedonia/Thrace</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O10">
            <title>DLQI Score Change Baseline to Month 12- Epirus</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O11">
            <title>DLQI Score Change Baseline to Month 12- Ionian Islands</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O12">
            <title>DLQI Score Change Baseline to Month 12- North Aegean</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O13">
            <title>DLQI Score Change Baseline to Month 12- Peloponnese</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O14">
            <title>DLQI Score Change Baseline to Month 12- South Aegean</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O15">
            <title>DLQI Score Change Baseline to Month 12- Thessaly</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O16">
            <title>DLQI Score Change Baseline to Month 12- West Greece</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O17">
            <title>DLQI Score Change Baseline to Month 12- West Macedonia</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Dermatology Life Quality Index (DLQI) Score by Physician’s Global Assessment of Disease Severity (PGA) Response Groups and by Geographical Region</title>
          <description>The average change in the Dermatology Life Quality Index (DLQI) score during the 12-month study was analyzed by the Physician’s Global Assessment of disease severity (PGA) response and also by geographical location of study participants. DLQI scores range from 0 to 30, with a higher score indicating a more impaired quality of life. . In this table, a higher number means a greater improvement in the participants’ quality of life.</description>
          <population>Participants with available data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="444"/>
                <count group_id="O3" value="433"/>
                <count group_id="O4" value="423"/>
                <count group_id="O5" value="237"/>
                <count group_id="O6" value="16"/>
                <count group_id="O7" value="65"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="1"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="15"/>
                <count group_id="O16" value="21"/>
                <count group_id="O17" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="6.5"/>
                    <measurement group_id="O2" value="9.6" spread="7.1"/>
                    <measurement group_id="O3" value="11.5" spread="7.7"/>
                    <measurement group_id="O4" value="12.3" spread="7.8"/>
                    <measurement group_id="O5" value="12.9" spread="8.5"/>
                    <measurement group_id="O6" value="14.9" spread="7.2"/>
                    <measurement group_id="O7" value="12.3" spread="6.4"/>
                    <measurement group_id="O8" value="11.2" spread="6.7"/>
                    <measurement group_id="O9" value="10.6" spread="6.1"/>
                    <measurement group_id="O10" value="2.0" spread="0.0"/>
                    <measurement group_id="O11" value="19.0"/>
                    <measurement group_id="O12" value="11.0" spread="7.7"/>
                    <measurement group_id="O13" value="6.8" spread="4.7"/>
                    <measurement group_id="O14" value="15.0" spread="4.2"/>
                    <measurement group_id="O15" value="9.5" spread="7.7"/>
                    <measurement group_id="O16" value="8.7" spread="7.2"/>
                    <measurement group_id="O17" value="12.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting &quot;No Problem&quot; on the European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D)</title>
        <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either “problem” or “no problem” with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
        <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <population>Participants with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>EQ5D- Mobility- Baseline</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>EQ5D- Mobility- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O3">
            <title>EQ5D- Mobility- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O4">
            <title>EQ5D- Mobility- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O5">
            <title>EQ5D- Mobility- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O6">
            <title>EQ5D- Self-care- Baseline</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O7">
            <title>EQ5D- Self-care- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O8">
            <title>EQ5D- Self-care- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O9">
            <title>EQ5D- Self-care- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O10">
            <title>EQ5D- Self-care- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O11">
            <title>EQ5D- Usual Activities- Baseline</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O12">
            <title>EQ5D- Usual Activities- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O13">
            <title>EQ5D- Usual Activities- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O14">
            <title>EQ5D- Usual Activities- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O15">
            <title>EQ5D- Usual Activities- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O16">
            <title>EQ5D- Pain/Discomfort- Baseline</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O17">
            <title>EQ5D- Pain/Discomfort- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O18">
            <title>EQ5D- Pain/Discomfort- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O19">
            <title>EQ5D- Pain/Discomfort- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O20">
            <title>EQ5D- Pain/Discomfort- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O21">
            <title>EQ5D- Anxiety/Depression- Baseline</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O22">
            <title>EQ5D- Anxiety/Depression- Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O23">
            <title>EQ5D- Anxiety/Depression- Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O24">
            <title>EQ5D- Anxiety/Depression- Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O25">
            <title>EQ5D- Anxiety/Depression- Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting &quot;No Problem&quot; on the European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D)</title>
          <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. The EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either “problem” or “no problem” with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
          <population>Participants with available data at each time point</population>
          <units>Percentage of patients with no problem</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="469"/>
                <count group_id="O4" value="445"/>
                <count group_id="O5" value="433"/>
                <count group_id="O6" value="500"/>
                <count group_id="O7" value="491"/>
                <count group_id="O8" value="469"/>
                <count group_id="O9" value="445"/>
                <count group_id="O10" value="432"/>
                <count group_id="O11" value="500"/>
                <count group_id="O12" value="491"/>
                <count group_id="O13" value="468"/>
                <count group_id="O14" value="445"/>
                <count group_id="O15" value="433"/>
                <count group_id="O16" value="500"/>
                <count group_id="O17" value="491"/>
                <count group_id="O18" value="469"/>
                <count group_id="O19" value="445"/>
                <count group_id="O20" value="431"/>
                <count group_id="O21" value="500"/>
                <count group_id="O22" value="491"/>
                <count group_id="O23" value="467"/>
                <count group_id="O24" value="445"/>
                <count group_id="O25" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6"/>
                    <measurement group_id="O2" value="66.2"/>
                    <measurement group_id="O3" value="90.2"/>
                    <measurement group_id="O4" value="91.5"/>
                    <measurement group_id="O5" value="90.8"/>
                    <measurement group_id="O6" value="81.2"/>
                    <measurement group_id="O7" value="84.3"/>
                    <measurement group_id="O8" value="92.1"/>
                    <measurement group_id="O9" value="95.3"/>
                    <measurement group_id="O10" value="94.2"/>
                    <measurement group_id="O11" value="66.2"/>
                    <measurement group_id="O12" value="77.8"/>
                    <measurement group_id="O13" value="90.2"/>
                    <measurement group_id="O14" value="92.1"/>
                    <measurement group_id="O15" value="94.5"/>
                    <measurement group_id="O16" value="56.2"/>
                    <measurement group_id="O17" value="73.1"/>
                    <measurement group_id="O18" value="87.2"/>
                    <measurement group_id="O19" value="90.3"/>
                    <measurement group_id="O20" value="93.3"/>
                    <measurement group_id="O21" value="20.8"/>
                    <measurement group_id="O22" value="36.9"/>
                    <measurement group_id="O23" value="53.7"/>
                    <measurement group_id="O24" value="67.6"/>
                    <measurement group_id="O25" value="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline of European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Visual Analogue Scale (VAS) Scores</title>
        <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either “problem” or “no problem” with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
        <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <population>Participants with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>EQ-5D VAS- Mean Change From Baseline-Month 1</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>EQ-5D VAS- Mean Change From Baseline-Month 4</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O3">
            <title>EQ-5D VAS- Mean Change From Baseline-Month 8</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
          <group group_id="O4">
            <title>EQ-5D VAS- Mean Change From Baseline-Month 12</title>
            <description>All eligible patients with psoriasis treated with Adalimumab</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline of European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Visual Analogue Scale (VAS) Scores</title>
          <description>EQ-5D (European Quality of Life - 5 Dimensions Questionnaire) is a standardized instrument for use as a measure of health outcome.
It has two components:
the EQ-5D descriptive system (i.e., the EQ-5D Index Score, comprised of five items), and
the EQ-5D VAS. EQ-5D Index Score has five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Patients reported either “problem” or “no problem” with each of the five dimensions of health. The EQ-5D VAS is a 20-cm scale with endpoints labeled &quot;best imaginable health&quot; and &quot;worst imaginable health&quot; anchored at 100 and 0, respectively.</description>
          <population>Participants with available data at each time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="491"/>
                <count group_id="O2" value="470"/>
                <count group_id="O3" value="445"/>
                <count group_id="O4" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="15.8"/>
                    <measurement group_id="O2" value="25.9" spread="20.5"/>
                    <measurement group_id="O3" value="31.8" spread="23.3"/>
                    <measurement group_id="O4" value="35.9" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Long Term Use and Safety of Adalimumab as Prescribed by the Dermatologist in a Normal Clinical Setting and in Accordance With the Terms of the European Marketing Authorization</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant, which did not necessarily have a causal relationship with their treatment. Any worsening of a pre-existing condition or illness was considered an adverse event.</description>
        <time_frame>12-month period (Month 0, Month 1, Month 4, Month 8, Month 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Psoriasis</title>
            <description>All eligible patients with psoriasis treated with Adalimumab were followed for the long term use and safety of Adalimumab. For more detailed information, please see the Adverse Events section.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Long Term Use and Safety of Adalimumab as Prescribed by the Dermatologist in a Normal Clinical Setting and in Accordance With the Terms of the European Marketing Authorization</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant, which did not necessarily have a causal relationship with their treatment. Any worsening of a pre-existing condition or illness was considered an adverse event.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data on adverse events were collected from study enrollment (Month 0) through Month 12.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With Psoriasis</title>
          <description>All eligible patients with psoriasis treated with Adalimumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oedema, peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electromyogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Spinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

